Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neupath Health Inc. ( (TSE:NPTH) ) has provided an update.
NeuPath Health Inc. reported record second-quarter revenue of $23.6 million, marking a 25% increase year-over-year, alongside a 69% rise in adjusted EBITDA to $2.2 million. The company’s improved financial performance is attributed to increased capacity utilization and strong demand for Arthrosamid, positioning NeuPath for continued growth and strategic expansion in the latter half of 2025.
The most recent analyst rating on (TSE:NPTH) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Neupath Health Inc. stock, see the TSE:NPTH Stock Forecast page.
More about Neupath Health Inc.
NeuPath Health Inc. operates a network of clinics specializing in chronic pain treatment. The company focuses on optimizing patient outcomes and enhancing clinic operations, with a market emphasis on innovative procedures such as Arthrosamid.
Average Trading Volume: 84,534
Technical Sentiment Signal: Buy
Current Market Cap: C$13.12M
For detailed information about NPTH stock, go to TipRanks’ Stock Analysis page.